Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1067 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Palatin starts obesity drug Phase 1 trial

Earlier, Palatin signed a research and licensing deal with AstraZeneca to develop, discover and commercialize compounds targeting melanocortin receptors to treat obesity, diabetes and related metabolic syndrome. The

Sigma Life Science extends Knockout ZFNs range

The increased capacity of the new manufacturing facility, together with advances in ZFN design algorithms and production processes, has led to cost reductions in the development and production

FDA accepts Rhucin Phase III trial design

Rhucin is under investigation as a treatment for acute attacks of angioedema for patients suffering from hereditary angioedema (HAE). The companies have received the FDA acceptance for Pharming’s

Orion, Nycomed sign deal for Easyhaler

The agreement covers Switzerland, Italy, Austria, the Benelux countries, Germany, France, Poland, Greece, Portugal, Spain and other European nations. Additionally, the companies have also signed a licensing and

Stellar signs pact with SAFC

As per the agreement, Stellar will be responsible for producing KLH commercial intermediate and supplying all aquaculture-derived KLH intermediate required for production of SAFC cGMP KLH formulations. However,